Larry W. Markham

Larry W. Markham

Auto-generated profile, based on publicly available information

Larry W. Markham

Vanderbilt University Medical Center, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JSJonathan H. Soslow
Jonathan H. Soslow
MXMeng Xu
Meng Xu
JSJames C. Slaughter
James C. Slaughter
KCKimberly Crum
Kimberly Crum
JKJacob A. Kaslow
Jacob A. Kaslow
LMLarry W. Markham
Larry W. Markham
Background: Cardiopulmonary failure is the leading cause of death in Duchenne muscular dystrophy (DMD). Research into DMD-specific cardiovascular therapies is ongoing, but there are no Food and Drug Administration-approved cardiac end points. To adequately power a therapeutic trial, appropriate end points must be chosen and the rate of change for these end points reported. The objective of this study was to evaluate rate of change for cardiac magnetic resonance and blood biomarkers and to determine which measures associate with all-cause mortality in DMD. Methods: Seventy-eight DMD subjects underwent 211 cardiac magnetic resonance studies analyzed for left ventricular (LV) ejection fraction, indexed LV end diastolic and systolic volumes, circumferential strain, late gadolinium enhancement presence and severity (global severity score, and full width half maximum), native T1 mapping, T2 mapping, and extracellular volume. Blood samples were analyzed for BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriuretic peptide), and troponin I. Cox proportional hazard regression modeling was performed with all-cause mortality as the outcome. Results: Fifteen subjects (19%) died. LV ejection fraction, indexed end systolic volumes, global severity score, and full width half maximum worsened at 1 and 2 years while circumferential strain and indexed LV end diastolic volumes worsened at 2 years. LV ejection fraction, indexed LV end diastolic and systolic volumes, late gadolinium enhancement full width half maximum, and circumferential strain associated with all-cause mortality ( P <0.05). NT-proBNP was the only blood biomarker that associated with all-cause mortality ( P <0.05). Conclusions: LV ejection fraction, indexed LV volumes, circumferential strain, late gadolinium enhancement full width half maximum, and NT-proBNP are associated with all-cause mortality in DMD and may be the best end points for use in cardiovascular therapeutic trials. We also report change over time of cardiac magnetic resonance and blood biomarkers.

20 February 2020 in Neuromuscular Disorders
Verified
Journal Article
Closed access
MKMary Killian
Mary Killian
MBMaciej Buchowski
Maciej Buchowski
TDThomas Donnelly
Thomas Donnelly
WBW. Bryan Burnette
W. Bryan Burnette
LMLarry W. Markham
Larry W. Markham
JSJonathan H. Soslow
Jonathan H. Soslow

Verified
Journal Article
Open access
PDF file
FRFrank J. Raucci
Frank J. Raucci
Anand Prakash SinghAnand Prakash Singh
Anand Prakash Singh
JSJonathan Soslow
Jonathan Soslow
LMLarry W. Markham
Larry W. Markham
LZLin Zhong
Lin Zhong
Cristi GalindoCristi Galindo
Cristi Galindo
Brain-derived neurotrophic factor (BDNF) is a neuronal growth and survival factor that harbors cardioprotective qualities that may attenuate dilated cardiomyopathy. In ~30% of the population, BDNF has a common, nonsynonymous single nucleotide polymorphism rs6265 (Val66Met), which might be correlated with increased risk of cardiovascular events. We previously showed that BDNF correlates with better cardiac function in Duchenne muscular dystrophy (DMD) patients. However, the effect of the Val66Met polymorphism on cardiac function has not been determined. The goal of the current study was to determine the effects of rs6265 on BDNF biomarker suitability and DMD cardiac functions more generally. We assessed cardiovascular and skeletal muscle function in human DMD patients segregated by polymorphic allele. We also compared echocardiographic, electrophysiologic, and cardiomyocyte contractility in C57/BL-6 wild-type mice with rs6265 polymorphism and in mdx/mTR (mDMD) mouse model of DMD. In human DMD patients, plasma BDNF levels had a positive correlation with left ventricular function, opposite to that seen in rs6265 carriers. There was also a substantial decrease in skeletal muscle function in carriers compared to the Val homozygotes. Surprisingly, the opposite was true when cardiac function of DMD carriers and non-carriers were compared. On the other hand, Val66Met wild-type mice had only subtle functional differences at baseline but significantly decreased cardiomyocyte contractility. Our results indicate that the Val66Met polymorphism alters myocyte contractility, conferring worse skeletal muscle function but better cardiac function in DMD patients. Moreover, these results suggest a mechanism for the relative preservation of cardiac tissues compared to skeletal muscle in DMD patients and underscores the complexity of BDNF signaling in response to mechanical workload.

1 December 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
JSJoseph Robert Starnes
Joseph Robert Starnes
JWJeffrey G. Weiner
Jeffrey G. Weiner
KGKristen George-Durrett
Kristen George-Durrett
KCKimberly Crum
Kimberly Crum
CHChristopher C. Henderson
Christopher C. Henderson
JSJonathan H. Soslow
Jonathan H. Soslow
BACKGROUND: Cardiomyopathy is the leading cause of death in boys with Duchenne muscular dystrophy (DMD). While cardiac magnetic resonance (CMR) is routinely used to assess fibrosis and left ventricular (LV) ejection fraction, CMR measures of LV filling and ejection in DMD have not been reported. METHODS: Patients with DMD (n=179) and healthy controls (n=96) were prospectively enrolled and underwent CMR. The DMD cohort was followed clinically at multiple institutions, and clinical data were recorded. Standard volumes and functions were calculated, and LV filling and ejection curves were measured from baseline CMR. Multivariable linear regressions were used to compare ventricular filling and ejection measures between groups, adjusting for baseline differences. Cox regressions were used to evaluate the relationship between diastolic function measures and mortality in the DMD cohort. RESULTS: Patients with DMD had significantly smaller stature and ventricular volumes than healthy control patients ( P <0.001). They had lower baseline LV ejection fraction ( P <0.001), though most had normal systolic function. When adjusted for age, sex, heart rate, body surface area, and LV end-diastolic volume, patients with DMD had slower peak filling rates ( P <0.001) and peak ejection rates ( P <0.001), as well as slower time to peak ventricular ejection rate ( P =0.011). When adjusted for heart rate, a lower peak ventricular ejection rate ( P =0.007) and peak filling rate ( P =0.033), normalized to LV end-diastolic volume, were associated with mortality in patients with DMD. CONCLUSIONS: Patients with DMD have significantly different baseline CMR filling and ejection indices compared with controls. Some filling indices are associated with mortality and may be useful prognostic measures. Further research is needed in larger cohorts to determine the prognostic value of these differences.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJoseph Robert Starnes
Joseph Robert Starnes
MXMeng Xu
Meng Xu
KGKristen George‐Durrett
Kristen George‐Durrett
KCKimberly Crum
Kimberly Crum
FRFrank J. Raucci
Frank J. Raucci
JSJonathan H. Soslow
Jonathan H. Soslow
Background: Cardiovascular disease is the leading cause of death among patients with Duchenne muscular dystrophy (DMD). Identifying patients at risk of early death could allow for increased monitoring and more intensive therapy. Measures that associate with death could serve as surrogate outcomes in clinical trials. Methods and Results: Duchenne muscular dystrophy subjects prospectively enrolled in observational studies were included. Models using generalized least squares were used to assess the difference of cardiac magnetic resonance measurements between deceased and alive subjects. A total of 63 participants underwent multiple cardiac magnetic resonance imaging and were included in the analyses. Twelve subjects (19.1%) died over a median follow‐up of 5 years (interquartile range, 3.1–7.0). Rate of decline in left ventricular ejection fraction was faster in deceased than alive subjects ( P <0.0001). Rate of increase in indexed left ventricular end‐diastolic ( P =0.0132) and systolic ( P <0.0001) volumes were higher in deceased subjects. Faster worsening in midcircumferential strain was seen in deceased subjects ( P =0.049) while no difference in global circumferential strain was seen. The rate of increase in late gadolinium enhancement, base T1, and mid T1 did not differ between groups. Conclusions: Duchenne muscular dystrophy death is associated with the rate of change in left ventricular ejection fraction, midcircumferential strain, and ventricular volumes. Aggressive medical therapy to decrease the rate of progression may improve the mortality rate in this population. A decrease in the rate of progression may serve as a valid surrogate outcome for therapeutic trials.

1 October 2024 in Disease Models & Mechanisms
Verified
Journal Article
Open access
CEConner C. Earl
Conner C. Earl
AJAreli J. Javier
Areli J. Javier
ARAlyssa M. Richards
Alyssa M. Richards
LMLarry W. Markham
Larry W. Markham
Craig GoergenCraig Goergen
Craig Goergen
Steven S WelcSteven S Welc
Steven S Welc
Cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy (DMD); however, in the mdx mouse model of DMD, the cardiac phenotype differs from that seen in DMD-associated cardiomyopathy. Although some have used pharmacologic stress to stimulate injury and enhance cardiac pathology in the mdx model, many methods lead to high mortality with variable cardiac outcomes, and do not recapitulate the structural and functional cardiac changes seen in human disease. Here, we describe a simple and effective method to enhance the cardiac phenotype model in mdx mice using advanced 2D and 4D high-frequency ultrasound to monitor cardiac dysfunction progression in vivo. mdx and wild-type mice received daily low-dose (2 mg/kg/day) isoproterenol injections for 10 days. Histopathological assessment showed that isoproterenol treatment increased myocyte injury, elevated serum cardiac troponin I levels and enhanced fibrosis in mdx mice. Ultrasound revealed reduced ventricular function, decreased wall thickness, increased volumes and diminished cardiac reserve in mdx compared to wild-type mice. Our findings highlight the utility of challenging mdx mice with low-dose isoproterenol as a valuable model for exploring therapies targeting DMD-associated cardiac pathologies.